Insider · CIK 0002095704
Boekhorst Paul Francis Olivier te
Files at ICCC (IMMUCELL CORP /DE/). First filing Dec 3, 2025, latest Jun 22, 2026.
In brief
Boekhorst Paul Francis Olivier te files SEC Form 4 as CEO, president and director at ICCC (IMMUCELL CORP /DE/). Since Dec 3, 2025, Boekhorst Paul Francis Olivier te has reported 3 open-market buys worth $156k and 0 open-market sells worth $0, the latest filed on Jun 22, 2026.
A track record needs three past buys with six months of prices behind them; Boekhorst Paul Francis Olivier te has 2, so none is measured yet.
The newest scored trade: bought $76k of ICCC on Jun 18, 2026, filed Jun 22, 2026, scored 43 (moderate). In the last 12 months: 3 buys worth $156k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ICCC: IMMUCELL CORP /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | ICCCbuy IMMUCELL CORP /DE/ | $76k 8,000 shares | +82% | +108% from low-11% from high | |
| 53Moderate | IMMUCELL CORP /DE/ | $32k 6,030 shares | +163% | - | |
| 48Moderate | IMMUCELL CORP /DE/ | $49k 9,785 shares | - | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | ICCC IMMUCELL CORP /DE/ | POpen-market purchase Common Stock, par value $.01 per share | +8,000 | $9.50 | $76k | 17,785 | Jun 22, 2026 |
| Jan 27, 2026 | ICCC IMMUCELL CORP /DE/ | AGrant or award Stock Options (right to buy)derivative | +109,500 | $0.00 | $0 | 109,500 | Mar 23, 2026 |
| Jan 27, 2026 | ICCC IMMUCELL CORP /DE/ | AGrant or award Stock Options (right to buy)derivative | +110,000 | $0.00 | $0 | 110,000 | Jan 29, 2026 |
| Dec 3, 2025 | ICCC IMMUCELL CORP /DE/ | POpen-market purchase Common Stock $0.10 par value per share | +3,598 | $5.05 | $18k | 7,306 | Dec 4, 2025 |
| Dec 4, 2025 | ICCC IMMUCELL CORP /DE/ | POpen-market purchase Common Stock $0.10 par value per share | +2,432 | $5.50 | $13k | 9,738 | Dec 4, 2025 |
| Dec 2, 2025 | ICCC IMMUCELL CORP /DE/ | POpen-market purchase Common Stock $0.10 par value per share | +3,708 | $4.87 | $18k | 3,708 | Dec 3, 2025 |
| Dec 3, 2025 | ICCC IMMUCELL CORP /DE/ | POpen-market purchase Common Stock $0.10 par value per share | +2,556 | $5.00 | $13k | 6,264 | Dec 3, 2025 |
| Dec 3, 2025 | ICCC IMMUCELL CORP /DE/ | POpen-market purchase Common Stock $0.10 par value per share | +3,521 | $5.04 | $18k | 9,785 | Dec 3, 2025 |
| Nov 7, 2025 | ICCC IMMUCELL CORP /DE/ | AGrant or award Stock Options (right to buy)derivative | +74,277 | $6.10 | $453k | 150,260 | Nov 12, 2025 |
Questions about Boekhorst Paul Francis Olivier te
Answered from the filings on this page, as of the latest one.
Is Boekhorst Paul Francis Olivier te buying or selling?
In the last 12 months Boekhorst Paul Francis Olivier te reported 3 open-market buys worth $156k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $76k of ICCC on Jun 18, 2026. Grants, option exercises and tax withholding are not counted.
How did Boekhorst Paul Francis Olivier te's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Boekhorst Paul Francis Olivier te has 2.
Where does Boekhorst Paul Francis Olivier te file Form 4?
Boekhorst Paul Francis Olivier te has filed Form 4 at ICCC (IMMUCELL CORP /DE/) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.